- Home
- ABOS vs ADVM Comparison
ABOS vs ADVM Comparison
Compare ABOS & ADVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABOS
- ADVM
- Stock Information
- Founded
- ABOS 1996
- ADVM 2006
- Country
- ABOS United States
- ADVM United States
- Employees
- ABOS N/A
- ADVM N/A
- Industry
- ABOS Biotechnology: Pharmaceutical Preparations
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ABOS Health Care
- ADVM Health Care
- Exchange
- ABOS Nasdaq
- ADVM Nasdaq
- Market Cap
- ABOS 109.6M
- ADVM 94.6M
- IPO Year
- ABOS 2021
- ADVM 2014
- Fundamental
- Price
- ABOS $1.55
- ADVM $4.26
- Analyst Decision
- ABOS Strong Buy
- ADVM Buy
- Analyst Count
- ABOS 3
- ADVM 5
- Target Price
- ABOS $8.00
- ADVM $11.60
- AVG Volume (30 Days)
- ABOS 275.1K
- ADVM 1.0M
- Earning Date
- ABOS 11-12-2025
- ADVM 11-12-2025
- Dividend Yield
- ABOS N/A
- ADVM N/A
- EPS Growth
- ABOS N/A
- ADVM N/A
- EPS
- ABOS N/A
- ADVM N/A
- Revenue
- ABOS N/A
- ADVM N/A
- Revenue This Year
- ABOS N/A
- ADVM $1,191.10
- Revenue Next Year
- ABOS N/A
- ADVM N/A
- P/E Ratio
- ABOS N/A
- ADVM N/A
- Revenue Growth
- ABOS N/A
- ADVM N/A
- 52 Week Low
- ABOS $0.86
- ADVM $1.78
- 52 Week High
- ABOS $2.66
- ADVM $7.73
- Technical
- Relative Strength Index (RSI)
- ABOS 35.12
- ADVM 49.17
- Support Level
- ABOS $1.74
- ADVM $4.25
- Resistance Level
- ABOS $2.04
- ADVM $4.36
- Average True Range (ATR)
- ABOS 0.16
- ADVM 0.08
- MACD
- ABOS -0.07
- ADVM -0.01
- Stochastic Oscillator
- ABOS 9.20
- ADVM 47.37
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.